Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy

On November 11, 2026 Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, reported that the RADIANZ ("Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89") clinical trial is enrolling patients. RADIANZ is an imaging study of ⁸⁹Zr-Barecetamab-DFO using PET to guide the pan-tumor development of ²²⁵Ac-Barecetamab-DOTA (ATNM-400) in solid tumors outside of prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RADIANZ builds on ATNM-400’s first-in-human Phase 1 study in metastatic castration-resistant prostate cancer (mCRPC). ATNM-400 is an investigational, first-in-class Actinium-225 antibody radioconjugate targeting HER3, an antigen implicated in tumor survival and treatment resistance across multiple solid tumors. Initial results from that study were presented in October 2026 as an oral presentation at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM). The first three patients received ATNM-400 at 1.0 µCi/kg with no dose-limiting toxicities, HER3-targeted PET imaging showed tumor uptake retained through Day 7, and dose escalation advanced to 1.5 µCi/kg. The mCRPC study was also featured in at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026. At EANM 2026, Actinium presented preclinical data in NSCLC, colorectal and ovarian cancer models demonstrating the potential of ATNM-400 either as a single agent of in combination with approved drugs. The Company will also present additional breast cancer data for ATNM-400 at the San Antonio Breast Cancer Symposium (SABCS) taking place December 8-11, 2026.

"Dosing the first patient in RADIANZ is a major step in our pan-cancer strategy for ATNM-400," said Sandesh Seth, Actinium’s Chairman and CEO. "The initial clinical results we presented at EANM and the study we highlighted at ESMO (Free ESMO Whitepaper) established ATNM-400 in the clinic in prostate cancer. Our preclinical work across lung, breast, colorectal and ovarian cancer models demonstrates HER3 targeting potential beyond prostate cancer. With RADIANZ, we are now testing that potential in patients and building a clinical path for ATNM-400 across several large, treatment-resistant patient populations."

RADIANZ Study Design

The RADIANZ imaging study will include patients with various tumor types, including NSCLC, breast, colorectal, pancreatic and ovarian cancers who have progressed on standard-of-care therapy. Patients receive Zirconium-89-barecetamab PET imaging with time points up to two weeks to demonstrate tumor retention of the antibody radioconjugate (ARC) in different cancer types over this time span. The study evaluates biodistribution, tumor uptake, pharmacokinetics (PK), and dosimetry across different tumor types.

"Many patients with advanced solid tumors have few options once standard therapies stop working," said Steffen Heeger, MD, Actinium’s Chief Medical Officer. "HER3 has been implicated in resistance to targeted therapies, chemotherapy and hormonal therapies across several solid tumors. The RADIANZ Imaging study will give us further insights on how ATNM-400 can be further developed in different solid tumors beyond prostate cancer. We are excited at the potential ATNM-400 offers as the first of its kind HER3 targeting radiotherapy and the opportunity to develop a truly differentiated pan cancer product."

About ATNM-400

ATNM-400 is an investigational antibody radioconjugate that pairs the HER3-targeting monoclonal antibody barecetamab with the alpha-emitting isotope Actinium-225. Its antibody-based design combines antigen-specific targeting with the potential for sustained tumor localization, supporting prolonged delivery of high-energy alpha radiation. Tumor uptake and retention observed through Day 7 with the ⁸⁹Zr-labeled imaging counterpart support this development rationale alongside the approximately 10-day half-life of ²²⁵Ac. The theranostic approach enables noninvasive visualization of antibody distribution to inform therapeutic development.

ATNM-400 is differentiated from PSMA-targeted radiotherapies by its focus on HER3, an antigen implicated in tumor survival and treatment resistance. PSMA-directed approaches include Novartis’ Pluvicto and a broad pipeline of investigational therapies, including Telix Pharmaceuticals’ TLX591-Tx, Clarity Pharmaceuticals’ ⁶⁷Cu-SAR-bisPSMA, Convergent Therapeutics’ CONV01-α, AstraZeneca’s AZD2265 (formerly FPI-2265), Curium’s lutetium-177 zadavotide guraxetan (¹⁷⁷Lu-PSMA-I&T), ARTBIO’s AB001 and AdvanCell’s ADVC001. These programs span small-molecule and antibody-based therapies using beta- or alpha-emitting isotopes. ATNM-400 combines HER3 targeting with an Actinium-225 antibody radioconjugate, offering a distinct biological approach with the potential to expand radiotherapy across the broad mCRPC population, including patients with PSMA-low or PSMA-negative disease and those who do not respond to or progress following PSMA-directed treatment. Its HER3-directed mechanism also supports investigation beyond prostate cancer in other HER3-expressing solid tumors.

About HER3

HER3, also known as ERBB3, belongs to the epidermal growth factor receptor family and participates in signaling pathways that promote tumor growth, survival and treatment resistance. HER3-directed antibody-drug conjugates (ADCs) in clinical development include BioNTech and MediLink’s BNT326/YL202; Bristol Myers Squibb and SystImmune’s EGFR × HER3 bispecific ADC, izalontamab brengitecan (iza-bren); and Daiichi Sankyo and Merck’s patritumab deruxtecan (HER3-DXd). These programs highlight clinical development interest in HER3 as an oncology target. ATNM-400 takes a different payload approach, delivering alpha radiation rather than a conventional cytotoxic drug. Preclinical activity in prostate, non-small cell lung, breast, colorectal and ovarian cancer models supports investigating ATNM-400 as a potential pan-cancer radiotherapy, both as monotherapy and in rational combinations.

(Press release, Actinium Pharmaceuticals, NOV 11, 2026, View Source [SID1234674609])

Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update

On November 11, 2026 Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) reported its financial results for the first nine months of 2026 and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At ASH (Free ASH Whitepaper), we look forward to sharing results from patients enrolled in company-sponsored trials, which we believe will further characterize the differentiated efficacy and safety profile of gamgertamig and its potential as a first- and best-in-class T-cell engager in autoimmune disease," said Henry Gosebruch, Chief Executive Officer of Lakefront.

"Our guidance for year-end 2026 cash and financial investments is at least €2 billion, including the recently completed share repurchase program and taking into account the decision to initiate a second €50 million share repurchase program, which is expected to be completed by the end of the first quarter of 2027," added Aaron Cox, Chief Financial Officer of Lakefront.

1 American Society of Hematology (ASH) (Free ASH Whitepaper)

Third Quarter 2026 Business Update
CORPORATE

Lakefront completed a €50 million share repurchase program on October 16, 2026. Under this completed program, 1.99 million shares were repurchased at an average price of €25.19.
Dr. Mehdi Shahidi has been appointed as Non-Executive Independent Board Director. He replaces Dr. Paulo Fontoura, who resigned from the Lakefront Board in July 2026 following his appointment as Global Head of R&D at Sanofi.
IMMUNOLOGY PORTFOLIO

A gamgertamig poster presentation highlighting data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an "immune reset", has been accepted for the 2026 American Society of Hematology (ASH) (Free ASH Whitepaper) Meeting. Investor webcast scheduled for Monday, December 14, 2026, at 8:00 AM ET.
Gamgertamig has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
Gamgertamig is expected to enter registrational studies in 2027.
Ongoing Lakefront-sponsored clinical trials of gamgertamig in autoimmune diseases are actively enrolling, and expansion of the clinical trials program is anticipated in 2027.
Phase 1b study with gamgertamig in patients with autoimmune cytopenias (including ITP and AIHA) (NCT07083960), active in Australia and the United States.
Phase 1b study with gamgertamig in seropositive autoimmune diseases (including idiopathic inflammatory myositis, Sjögren’s disease, pemphigus vulgaris (PV), and pemphigus foliaceus (PF)) (NCT07229144), active in Australia, New Zealand, Czech Republic, and Japan.
Multicenter, long-term follow-up study in participants who previously participated in a gamgertamig clinical study (NCT07847892) initiated in September 2026.
Lakefront expects to initiate proof-of-concept basket studies assessing gamgertamig in additional autoimmune indications in the first half of 2027.
In addition, Keymed is conducting a number of company-sponsored studies in Greater China with gamgertamig in both malignant and autoimmune indications.
Lakefront continues to progress the preclinical portfolio of three autoimmune and inflammatory disease programs originally from Ouro Medicines (Ouro) with an opt-in for Gilead Sciences (Gilead) for a 50/50 profit split post clinical proof-of-concept for $75 million per program.
GLPG3667 discontinuation: Lakefront has completed a rigorous analysis of the competitive landscape and market opportunity. Following extensive discussions with potential strategic partners, the Company has decided to discontinue the program. The cost associated with this discontinuation is not expected to be material.
ONCOLOGY CAR-T CELL THERAPY UPDATE

The Company announced the start of the wind-down of its cell therapy activities in January 2026. At the date of this press release, the wind-down is substantially complete, with the last wave of departures of impacted personnel expected before year-end and limited remaining costs for the fourth quarter of 2026 and beyond, primarily associated with the HESPERIA study.
To support long-term patient follow-up, the HESPERIA study continues to monitor safety of all patients treated in the discontinued parent studies; associated spending is expected to remain minimal.
Post-period Event

On October 14, 2026, Lakefront completed the sale of its next-generation early-stage cell therapy pipeline to Armed Cell Therapeutics BV for €8 million upfront and the potential for up to $230 million in milestone payments and a low-single-digit royalty to Lakefront. This program is based on technology originated from and research undertaken by AboundBio, which was acquired by Lakefront Biotherapeutics NV (previously Galapagos NV) in 2022.
The Board of Directors of Lakefront has approved a second €50 million share repurchase program. This second share repurchase program will be initiated shortly, with completion expected by the end of the first quarter of 2027. For further details, we refer to the press release to be issued upon launch of the program.
Financial Guidance

The Company expects its year-end 2026 cash and financial investments balance to be in the range of €2.0 to €2.05 billion. This guidance includes initiating a second €50 million share repurchase program, which was not considered in the previous guidance range.
Lakefront forecasts having at least €1.6 billion of its cash remaining for additional strategic transactions and other capital allocation priorities following funding the portfolio to first gamgertamig approval.
Lakefront expects to change the presentation currency of its consolidated financial statements for the year ending December 31, 2026, from the euro to the U.S. dollar, and to change the functional currency from the euro to the U.S. dollar effective January 1, 2027. These changes are intended to better reflect the increasingly U.S. dollar-denominated nature of the Company’s operations and financial profile.
All guidance figures assume a EUR/USD exchange rate of 1.175, consistent with year-end 2025 and prior guidance. As of September 30, 2026, the EUR/USD exchange rate was 1.1355.
These estimates are subject to change and depend on exchange rate fluctuations and future business development activity.

Financial Performance
Key figures for the first nine months of 2026 (consolidated)
(€ millions, except basic & diluted earnings/loss (-) per share)

Nine months ended September 30,

% Change
2026 2025
Supply revenues 17.7 29.3 -40%
Collaboration revenues 8.4 182.1 -95%
Total net revenues 26.1 211.4 -88%
Cost of sales (17.6) (29.3) -40%
R&D expenses (82.5) (351.9) -77%
G&Ai and S&Mii expenses (76.6) (109.0) -30%
Impairment of the cell therapy activities (204.8)
Other operating income 2.2 21.4 -90%
Operating loss (148.4) (462.2) -68%
Fair value adjustments and net exchange differences 119.0 (50.5)
Net other financial result 37.1 30.4
Income taxes (0.2) 19.3
Net profit/loss (-) from continuing operations 7.5 (463.0)
Net profit from discontinued operations, net of tax 6.4 1.7
Net profit/loss (-) of the period 13.9 (461.3)
Basic and diluted earnings/loss (-) per share (€) 0.2 (7.0)
Financial investments, cash and cash equivalents 2,183.1 3,050.1

Details of the financial results for the first nine months of 2026

Total operating loss from continuing operations for the first nine months of 2026 amounted to €148.4 million, compared to an operating loss of €462.2 million for the first nine months of 2025. The operating loss in 2025 was negatively impacted by an impairment on the cell therapy activities of €204.8 million as a result of the Company’s announced strategic alternatives process for the cell therapy activities, and the executed strategic reorganization announced in January 2025, for €135.5 million. The latter was reflected in severance costs of €47.5 million, costs for early termination of collaborations of €45.5 million, impairment on fixed assets related to small molecules activities of €9.5 million, professional services costs of €21.4 million, €9.8 million accelerated non-cash cost recognition for subscription right plans and €1.8 million other operating expenses.

Total net revenues amounted to €26.1 million for the first nine months of 2026, compared to €211.4 million for the first nine months of 2025. The revenue recognition related to the exclusive access rights granted to Gilead for Lakefront’s drug discovery platform amounted to €172.6 million for the first nine months of 2025. The deferred income related to the drug discovery platform was fully released in revenue at the end of 2025.
Cost of sales amounted to €17.6 million for the first nine months of 2026, compared to €29.3 million for the first nine months of 2025, and related to the supply of Jyseleca to Alfasigma under the transition agreement. The related revenues are reported in total net revenues.
R&D expenses amounted to €82.5 million for the first nine months of 2026, compared to €351.9 million for the first nine months of 2025. In the first nine months of 2025, the Company recorded increased personnel expenses (mainly related to severance costs), an impairment on fixed assets (related to small molecules programs) and a provision for early termination of collaboration agreements. Additionally, due to the wind-down of the cell therapy activities, the spending in the CAR-T programs decreased in the first nine months of 2026 as compared to the first nine months of 2025.
G&A and S&M expenses amounted to €76.6 million for the first nine months of 2026, compared to €109.0 million for the first nine months of 2025. This decrease was mainly due to lower personnel costs (primarily severance costs).
Impairment of the cell therapy activities in 2025 is a result of the Company’s previously announced strategic alternatives process for the cell therapy activities whereby the Company assessed the recoverable amount of the cell therapy activities’ associated assets in accordance with International Accounting Standard 36. The recoverable amount was estimated to be lower than the assets’ carrying value. As a result, the Company recognized an impairment loss of €204.8 million for the first nine months of 2025, thereby aligning the cell therapy assets’ book value with the Company’s strategic intention to wind down the cell therapy activities, which resulted in a full impairment of both the associated goodwill and intangible assets and a partial impairment of property, plant and equipment.
Other operating income amounted to €2.2 million for the first nine months of 2026, compared to €21.4 million for the first nine months of 2025, mainly driven by lower R&D incentives income.
Net financial income amounted to €156.1 million for the first nine months of 2026, compared to net financial loss of €20.1 million for the first nine months of 2025.

Fair value adjustments and net currency exchange results amounted to a positive amount of €119.0 million for the first nine months of 2026, compared to a negative amount of €50.5 million for the first nine months of 2025, and were primarily attributable to €68.3 million of positive changes in fair value of financial investments and €42.0 million of unrealized currency exchange gains on Lakefront’s cash and cash equivalents and financial investments at amortized cost in U.S. dollars.
Net other financial income amounted to €37.1 million for the first nine months of 2026, compared to net other financial income of €30.4 million for the first nine months of 2025. Interest income amounted to €35.6 million for the first nine months of 2026, compared to €31.4 million of interest income for the first nine months of 2025. Fair value gains and interest income derived from cash, cash equivalents and financial investments excluding any currency exchange results amounted to €68.2 million for the first nine months of 2026 (compared to €77.2 million for the same period last year).
Income taxes amounted to a negative amount of €0.2 million for the first nine months of 2026, compared to positive income taxes of €19.3 million in the same period last year. The major amount in 2025 can be mainly explained by the reversal of the deferred tax liabilities linked to capitalized intangible assets related to the cell therapy activities, as the Company recorded an impairment on these intangible assets.

The Company reported a net profit from continuing operations of €7.5 million for the first nine months of 2026, compared to a net loss from its continuing operations of €463.0 million for the first nine months of 2025.

Net profit from discontinued operations related to Jyseleca amounted to €6.4 million for the first nine months of 2026, compared to net profit amounting to €1.7 million for the first nine months of 2025.

Lakefront reported a net profit of €13.9 million for the first nine months of 2026, compared to a net loss of €461.3 million for the first nine months of 2025.

Cash position
Financial investments and cash and cash equivalents totaled €2,183.1 million on September 30, 2026, as compared to €2,998.0 million on December 31, 2025. The cash and cash equivalents and financial investments included $2,150.2 million held in U.S. dollars ($2,159.0 million on December 31, 2025) which could generate foreign exchange gains or losses in the financial results in accordance with the fluctuation of the EUR/U.S. dollar exchange rate as the Company’s functional currency is EUR (translated at a rate of 1.1355 €/$ at September 30, 2026).

Total net decrease in cash and cash equivalents and financial investments amounted to €814.9 million during the first nine months of 2026, compared to a net decrease of €267.7 million during the first nine months of 2025. This net decrease was composed of (i) €97.2 million of operational cash burniii, which includes cash in of €88.2 million related to the return on financial investments, (ii) €58.4 million of positive exchange rate differences, positive changes in fair value of current financial investments, variation in accrued interest income, (iii) €1.1 million, which includes acquisition of equity investments and the issuance of a convertible loan, (iv) €6.1 million of net cash in related to the sale of subsidiaries, (v) €40.8 million purchase of own shares and (vi) €740.3 million cash out related to the purchase of Ouro Medicines.

(Press release, Lakefront Biotherapeutics, NOV 11, 2026, View Source [SID1234674625])

Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate

On November 11, 2026 Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest"), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, reported that it has exercised its option under its agreement with Hebei Senlang Biotechnology Co., Ltd. ("Senlang") to obtain an exclusive license to develop and commercialize Senlang’s CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates worldwide, excluding China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CD7-targeted lentiviral platform is designed to deliver CAR payloads into the patient’s own immune cells, complementing Tempest’s existing lipid nanoparticle (LNP) delivery platform, for the in vivo generation of antigen-directed CAR-T cells. The lead program is SL4903, which Tempest is designating TPST-4903, a BCMA/GPRC5D dual-targeting candidate being studied in relapsed or refractory multiple myeloma (rrMM). By targeting two clinically validated targets in rrMM, TPST-4903 may reach a broader range of malignant plasma cells and limit tumor escape resulting from the loss or reduced expression of either target. The license also provides access to additional in vivo CAR-T candidates for potential development in blood cancers, solid tumors, and autoimmune conditions.

"Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program," said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. "We are encouraged by the emerging clinical data from the ongoing DELIVER-1 Phase 1 dose-escalation study of TPST-4903, which includes multiple myeloma patients with a substantial unmet need for new treatment options, such as those with extramedullary disease and those previously treated with CAR-T therapy. We look forward to sharing the detailed results with the scientific community."

At the data cutoff for the current analysis, 13 patients in the DELIVER-1 study had received TPST-4903. The study population includes heavily pretreated patients with rrMM, including patients with extramedullary disease (EMD) and patients who previously received a BCMA-targeted CAR-T therapy. Tempest believes that preliminary observations of clinical activity and tolerability are encouraging and support further evaluation. The findings remain early, and additional follow-up is needed to characterize the benefit-risk profile. The data are expected to be presented at a major scientific conference.

"With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease," said Dr. Angel. "We continue to believe that these complementary platforms provide Tempest with the flexibility to match the delivery approach to the biology and treatment requirements of different cancers and autoimmune diseases."

Tempest originally announced the exclusive option agreement with Senlang in September 2026. The license is subject to the financial obligations and development requirements set out in that agreement.

About TPST-4903, DELIVER-1, and Tempest’s CD7-Directed Lentiviral Platform

TPST-4903 is an investigational in vivo CAR-T therapy targeting BCMA and GPRC5D and delivered using a CD7-targeted lentiviral vector. DELIVER-1 (NCT07586709) is a single-center, open-label Phase 1 dose-escalation study enrolling patients with rrMM who have received at least two prior lines of therapy. The study is evaluating safety, tolerability, preliminary antimyeloma activity, and pharmacokinetic and pharmacodynamic characteristics. Tempest’s CD7-directed lentiviral platform, exclusively licensed from Senlang, includes a pipeline of clinical and preclinical-stage in vivo CAR-T programs, which are designed to selectively deliver CAR payloads to endogenous CD7-positive T cells and NK cells, enabling in vivo generation of antigen-directed CAR immune cells.

(Press release, Tempest Therapeutics, NOV 11, 2026, View Source [SID1234674610])

PHP Biotech Reports Preclinical Efficacy and Safety Data for PHP53-nb, a First-in-Class Nanobody for Mutant-p53 Tumors

On November 11, 2026 PHP Biotech International Inc., a privately held biotechnology company developing humanized nanobody therapeutics for aggressive solid tumors, reported preclinical efficacy, safety and biodistribution results for its lead candidate, PHP53-nb, and outlined the experimental program it expects to complete ahead of regulatory testing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PHP53-nb is a first-in-class humanized camelid nanobody engineered to induce apoptosis in tumor cells carrying mutant p53 — a mutation class that has resisted conventional drug development for decades. At roughly one-tenth the size of a conventional monoclonal antibody, the molecule potentially carries lower immunogenicity, greater stability and more efficient tissue and tumor penetration. It selectively targets a receptor expressed on tumor cells, uPAR, an for internalization, then acts inside the cell through proteasome modulation, ER stress and unfolded protein response activation, mitochondrial permeabilization and caspase cascade activation.

Activity across multiple p53 mutations. In a twelve-line cell panel, PHP53-nb decreased cell viability in tumor lines carrying both DNA-binding-domain and structural TP53 mutations: triple-negative breast cancer (MDA-MB-231, R280K; HCC1395, R175H), pancreatic cancer (MiaPaCa-2, R248W; Su86.86, G245S; BxPC-3, Y220C), non-small cell and small cell lung cancer (NCI-H820, T284P; NCI-H1963, H214R), osteosarcoma (KHOS/NP, R156P) and neuroblastoma (SK-N-BE(2), C135F). All results were statistically different from the non-tumorigenic MCF10A control. A wide safety margin. In zebrafish, no lethality was observed up to 20 times the MDA-MB-231 in vitro IC50, and malformations appeared only at concentrations at or above that threshold (p<0.0001). Published work places doxorubicin’s LD50 at six times plasma concentration in the same model. At non-toxic doses, PHP53-nb produced tumor growth reduction comparable to doxorubicin in zebrafish TNBC xenografts, with activity observed against both primary tumor and metastatic burden.

In vivo results in mice. In a triple-negative breast cancer xenograft model, PHP53-nb dosed at 200 mg/kg achieved 41% tumor growth inhibition by day 29, compared with 59% for paclitaxel at 15 mg/kg (p<0.05, two-sided Welch’s t-test versus vehicle). Fluorescent biodistribution imaging at 20 mg/kg showed efficient systemic distribution, delivery to the target tissue, and persistent tumor localization at least 24 hours after administration — addressing rapid clearance and low target retention, two limitations that have historically constrained nanobody development.

"Mutant p53 sits inside a large share of human cancers, and the field has spent decades trying to reach it," said Robert Gahagen, Chief Executive Officer of PHP Biotech. "What these data show is a molecule that gets inside the cell, works across several different mutations rather than one, and does it with a safety margin that leaves real room to dose. That combination is what makes this a program worth partnering on."

PHP53-nb is built on GEN01-AD, PHP Biotech’s proprietary nanobody platform. The scaffold embeds a theragnostic sequence directly in the nanobody paratope, producing a single recombinant molecule with no linker or conjugation chemistry — a design intended to lower manufacturing cost and improve commercial viability. GEN01-AD can carry other bioactive sequences as well, with potential applications in immunology, antimicrobial therapy, imaging and metabolic disease alongside oncology. Four patents covering the peptide, the scaffold, the production method and the lead molecule have been filed in the United States and under the Patent Cooperation Treaty.

"The scaffold is what makes the rest possible," said Patrícia Bezerra, PhD, Research Leader at PHP Biotech. "It gives bioactive sequences stability and a possible route into the cell, and it manufactures like a single protein rather than a conjugate. The same chassis can generate multispecifics, antibody-drug conjugates and radioligands."

. PHP Biotech’s analysis of GLOBOCAN 2022, IARC TP53 Database v20, COSMIC v98 and TCGA PanCancer Atlas data across eight tumor types puts five-year prevalence at approximately 9.61 million patients, of whom roughly 5.52 million carry a TP53 mutation and about 828,000 carry one of the three hotspot variants represented in the company’s responsive cell panel — R175H, G245S and R280K.

Planned work through the first quarter includes mechanism-of-action validation, toxicity and efficacy studies in mice, ADME and blood-brain-barrier studies, an in vivo combination study with anti-PD-1 therapy, technology transfer to a contract development and manufacturing organization, and regulatory testing. The program is supported by research and manufacturing partners including ATUM, BioReperia, TD2 Precision Oncology, Pace Life Sciences, Thermo Fisher Scientific, PanomeBio and RayBiotech.

PHP Biotech is engaged in partnering discussions with pharmaceutical companies and investors evaluating PHP53-nb as both a standalone candidate and an add-on therapeutic in tumors carrying p53 mutations.

(Press release, PHP Biotech, NOV 11, 2026, View Source [SID1234674626])

Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds

On November 11, 2026 Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, reported that the Company has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of 2,777,778 shares of common stock of the Company ("common stock") at a reduced exercise price of $1.08 per share. In consideration for such cash exercises, the Company will issue new unregistered common stock purchase warrants (the "Inducement Warrants") to purchase up to an aggregate of 13,888,890 shares of common stock at an exercise price of $1.08 per share. The Inducement Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire five years after their initial exercise date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-298483).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The aggregate gross proceeds from the transaction described herein are expected to total approximately $3.0 million, before deducting placement agent fees and expenses.

Roth Capital Partners is acting as the Company’s financial advisor in connection with this transaction.

The transaction is expected to close on or about November 12, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the transaction for working capital purposes.

The Inducement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933 (the "Securities Act"). The Inducement Warrants, along with the common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the New Warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or exemption under the securities laws of any such state or jurisdiction.

(Press release, Aptevo Therapeutics, NOV 11, 2026, View Source [SID1234674611])